Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the
chronic hyperactivation of the immune system and (partly) prevent the decrease of the CD4+
T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral
therapy (ART). The researchers also want to know what the effect is of treatment with MMF on
plasma HIV-1 RNA; progression of disease (occurrence of AIDS defining events or reaching the
indication to start ART); and the safety of treatment with MMF in this patient group.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Hoffmann-La Roche Sanquin Research & Blood Bank Divisions